


**AMENDMENTS TO THE CLAIMS**

1. (Currently amended) A compound of the following formula:



or a pharmaceutically acceptable salt or N-oxide thereof;

wherein


A is ~~aryl or heteroaryl~~;


B is ~~N or CR<sup>2</sup>~~;

each of R<sup>2</sup> and R<sup>3</sup> is independently hydrogen, alkyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, or heteroaralkyl;

each of X<sup>1</sup> and X<sup>2</sup> is independently hydrogen, C<sub>1-6</sub> alkylene, C<sub>2-6</sub> alkenylene, C<sub>2-6</sub> alkynylene or a bond;

L is a bond or a linker selected from the group consisting of:





wherein:

each of  $R'$  and  $R''$ , independently, is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, sulfoxy, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxy carbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroaryl sulfanyl, or heteroaroyl; provided that two adjacent  $R'$  groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety;

$R^a$  is  $-C(R^2)(R^3)-$ ,  $-S-$ ,  $-SO-$ , or  $-SO_2-$ ;

$R^b$  is  $-C(R^2)(R^3)-$ ,  $-NR^2-$ ,  $-O-$ ,  $-S-$ ,  $-SO-$ , or  $-SO_2-$ ;

each of  $p$ ,  $q$ ,  $m$  and  $m1$ , independently, is 0-3;

$r$  is 1 or 2;


$n1$  is 0-6; and

$n2$  is 2-6;


Y is  $-C(R^2)(R^3)-$ ,  $-O-$ ,  $-S-$ ,  $-SO-$ ,  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond; and

$R^1$  is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, or heterocycloalkyl;

provided that (1) when each of  $X^1$  is a bond and L is a 4- to 6-membered saturated heterocyclic group selected from the group consisting of:



2. (Original) The compound of claim 1, wherein  $X^1$  is  $C_{2-6}$  alkynylene.




4. (Original) The compound of claim 2, wherein  $X^2$  is  $C_{1-4}$  alkylene or a bond.

5. (Original) The compound of claim 2, wherein Y is a bond.


6. (Original) The compound of claim 2, wherein each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl.

7. (Original) The compound of claim 2, wherein  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.


8. (Original) The compound of claim 7, wherein  $R^1$  is optionally substituted with alkyl, halo, hydroxy or phenyl.



9. (Original) The compound of claim 2, wherein L is or a bond;  $X^2$  is C1-4 alkylene or a bond; Y is a bond; each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl;  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl; A is heteroaryl; and B is N.



10. (Original) The compound of claim 1, wherein L is




11. (Original) The compound of claim 10, wherein  $X^b$  is  $-C(R^2)(R^3)-$  or  $-NR^2-$ .

12. (Original) The compound of claim 11, wherein  $X^b$  is  $-C(R^2)(R^3)-$ .

13. (Original) The compound of claim 12, wherein p is 0-1 and q is 1.


14. (Original) The compound of claim 13, wherein  $n_1$  is 1-4 and  $n_2$  is 2-4.

15. (Original) The compound of claim 14, wherein  $X^1$  is  $C_{1-6}$  alkylene or a bond.
16. (Original) The compound of claim 14, wherein  $X^2$  is  $C_{1-6}$  alkylene or a bond.
17. (Original) The compound of claim 14, wherein Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond.
18. (Original) The compound of claim 14, wherein each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl.
19. (Original) The compound of claim 14, wherein  $R^1$  is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl.
20. (Original) The compound of claim 14, wherein each of  $X^1$  and  $X^2$  is independently  $C_{1-6}$  alkylene or a bond; Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond; each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl; and  $R^1$  is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl.



21. (Original) The compound of claim 14, wherein L is  $;$ ;  $X^1$  is a bond,  $X^2$  is  $C_{1-4}$  alkylene; Y is a bond; each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl;  $R^1$  is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl; A is heteroaryl; and B is N.

22. (Original) The compound of claim 1, wherein L is



23. (Original) The compound of claim 22, wherein  $X^1$  is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkynylene, or a bond.

24. (Original) The compound of claim 22, wherein  $X^2$  is  $C_{1-6}$  alkylene or a bond.

25. (Original) The compound of claim 22, wherein Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond.

26. (Original) The compound of claim 22, wherein each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl.

27. (Original) The compound of claim 22, wherein  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.

28. (Original) The compound of claim 27, wherein  $R^1$  is optionally substituted with alkyl, halo, hydroxy or phenyl.

29. (Original) The compound of claim 22, wherein  $X^1$  is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkynylene, or a bond,  $X^2$  is  $C_{1-6}$  alkylene or a bond; Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond; each of  $R^2$  and  $R^3$  is independently hydrogen or alkyl;  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl, each of which is being optionally substituted with alkyl, halo, hydroxy, or phenyl; A is heteroaryl; and B is N.

30. (Original) The compound of claim 1, said compound being

2-furan-2-yl-N<sup>5</sup>-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

2-furan-2-yl-N<sup>5</sup>-methyl-N<sup>5</sup>-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

N<sup>5</sup>-[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;

5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]propyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;

5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5,7-diamine;

N<sup>5</sup>-{2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;

2-furan-2-yl-N<sup>5</sup>-(1-furan-2-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

N<sup>5</sup>-[1-(2-fluorobenzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

2-furan-2-yl-N<sup>5</sup>-(1-pyridin-2-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

2-furan-2-yl-N<sup>5</sup>-(1-pyridin-4-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

2-furan-2-yl-N<sup>5</sup>-(1-(2,3,6-trifluorobenzyl)-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

N<sup>5</sup>-[1-(2-chloro-pyridin-4-ylmethyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-cyclopentanol;

1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-cyclohexanol;

2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

$N^5$ -{2-[4-(2,3-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 2-furan-2-yl- $N^5$ -{2-[4-(3,4,5-trifluorophenyl)-piperazin-1-yl]-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 2-furan-2-yl- $N^5$ -{2-[4-(2,3,6-trifluorophenyl)-piperazin-1-yl]-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 $N^5$ -{2-[4-(3,5-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 $N^5$ -{2-[4-(2,6-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 $N^5$ -{2-[4-(2,5-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 $N^5$ -{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 $N^5$ -{2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 $N^5$ -{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 2-furan-2-yl- $N^5$ -{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 2-furan-2-yl- $N^5$ -{2-[4-(2,4,5-trifluorophenyl)-piperazin-1-yl]-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and  
 $N^5$ -{2-[4-(4-chloro-2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

31. (Original) The compound of claim 1, said compound being

2-furan-2-yl- $N^5$ -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-  
 [1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
 2-furan-2-yl- $N^5$ -methyl- $N^5$ -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-  
 [1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;



2-furan-2-yl-N<sup>5</sup>-(1-furan-2-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
2-furan-2-yl-N<sup>5</sup>-(1-(2,3,6-trifluorobenzyl)-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-[1-(2-chloro-pyridin-4-ylmethyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-pentanol;  
1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-cyclohexanol;  
5-(3-cyclohexyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
N<sup>5</sup>-{2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(2,3-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,3,6-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine.

32. (Original) The compound of claim 1, said compound being

2-furan-2-yl-N<sup>5</sup>-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-  
[1,2,4]triazolo[1,5-a]pyridimidine-5,7-diamine;  
2-furan-2-yl-N<sup>5</sup>-methyl-N<sup>5</sup>-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-  
[1,2,4]triazolo[1,5-a]pyridimidine-5,7-diamine;  
N<sup>5</sup>-[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidine-5,7-diamine;  
5-(3-cyclohexyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidin-7-ylamine;  
N<sup>5</sup>-{2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidin-7-ylamine;  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-  
a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidine-5,7-diamine; and  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl-[1,2,4]triazolo[1,5-  
a]pyrimidine-5,7-diamine.

33. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
34. (Original) A pharmaceutical composition comprising a compound of claim 30 and a pharmaceutically acceptable carrier.
35. (Cancelled)
36. (Cancelled)
37. (Cancelled)

- 38. (Cancelled)
- 39. (Cancelled)
- 40. (Cancelled)
- 41. (Cancelled)
- 42. (Cancelled)
- 43. (Cancelled)
- 44. (Cancelled)
- 45. (Cancelled)
- 46. (Cancelled)
- 47. (New) The compound of claim 10, wherein  $X^1$  is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkynylene or a bond.
- 48. (New) The compound of claim 47, wherein  $R^2$  is hydrogen or alkyl.
- 49. (New) The compound of claim 48, wherein  $X^2$  is  $C_{1-6}$  alkylene or a bond.
- 50. (New) The compound of claim 49, wherein Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond.
- 51. (New) The compound of claim 50, wherein  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.

52. (New) The compound of claim 51, wherein  $R^1$  is a substituted aryl (e.g., 2,4-difluorophenyl).
53. (New) The compound according to claim 10, wherein  $X^1$  is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkynylene or a bond; Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond;  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl; and  $X^2$  is  $C_{1-6}$  alkylene or a bond.